Table 1.
Patient, disease, and treatment characteristics.
| Total sample N =95, % | Gain 1q N =20, % | No gain 1q N =75, % | p Value | |
|---|---|---|---|---|
| Age, Median (Range) | 58 (29–73) | 55 (32–71) | 58 (29–73) | .1 |
| Male | 60 (63) | 16 (80) | 44 (57) | .12 |
| Race | .89 | |||
| Caucasian | 74 (78) | 15 (75) | 59 (79) | |
| African American | 17 (18) | 4 (20) | 13 (17) | |
| Other | 4 (4) | 1 (5) | 3 (4) | |
| Isotype | .44 | |||
| IgG | 51 (54) | 14 (70) | 37 (49) | |
| IgA | 20 (21) | 3 (15) | 17 (23) | |
| Kappa | 13 (14) | 1 (5) | 12 (16) | |
| Lambda | 11 (12) | 2 (10) | 9 (12) | |
| ISS stage | >.99 | |||
| I | 49 (52) | 10 (50) | 39 (52) | |
| II | 27 (28) | 6 (30) | 21 (28) | |
| III | 19 (20) | 4 (20) | 15 (20) | |
| BM PC, % (range) | 37 (2–94) | 40 (3–82) | 36 (2–94) | .26 |
| Lytic lesions | 79 (83) | 19 (95) | 60 (80) | .18 |
| Extramedullary disease | 45 (47) | 13 (65) | 32 (43) | .085 |
| CNS disease | 1 (1) | 1 (5) | 0 | .21 |
| Creatinine >2mg/dL | 5 (5) | 1 (5) | 4 (5) | >.99 |
| Karyotype | .01 | |||
| Normal/single abnormality | 61 (64) | 8 (40) | 53 (71) | |
| Complex | 22 (23) | 10 (50) | 12 (16) | |
| Not done/not adequate | 12 (13) | 2 (10) | 10 (13) | |
| FISH | ||||
| Any abnormality | 75 (56) | 25 (100) | 50 (46) | <.001 |
| High risk | 14 (15) | 4 (20) | 10 (13) | .33 |
| 11q23 (MLL) | 29 (31) | 10 (50) | 19 (25) | .078 |
| Del13q | 25 (26) | 11 (55) | 14 (19) | .004 |
| Treatment | ||||
| Induction | .16 | |||
| Lenalidomide based | 24 (25) | 3 (15) | 21 (28) | |
| Bortezomib based | 37 (39) | 7 (35) | 30 (40) | |
| RVD | 33 (35) | 9 (45) | 24 (32) | |
| Required additional induction | 15 (16) | 3 (15) | 12 (16) | >.99 |
| Tandem HCT | 7 (7) | 1 (5) | 6 (8) | >.99 |
| Maintenance after HCT | 73 (77) | 15 (75) | 58 (77) | .78 |
| Allogeneic HCT | 14 (15) | 8 (40) | 6 (8) | .001 |
BM PC: bone marrow plasma cells; CNS: central nervous system; Del13q, deletion of chromosome 13q or monosomy 13 by FISH; FISH: fluorescence in-situ hybridization; Gain 1q: Gain of chromosome 1q21 or 1q25 by FISH; HCT: hematopoietic cell transplantation; High risk, deletion 17p, t(4;14), or t(14;16) by FISH; ISS: International Staging System; MLL: mixed lineage leukemia gene; RVD: lenalidomide, bortezomib, dexamethasone.